114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于倾向评分匹配的黄芪多糖注射液辅助治疗非小细胞肺癌疗效及生存预后分析
Authors Li J, Zhang Y, Wang X, Ding Z, Zhu N, Chen Y, Li Y, Lu C
Received 31 July 2025
Accepted for publication 15 November 2025
Published 31 December 2025 Volume 2025:17 Pages 3359—3372
DOI https://doi.org/10.2147/CMAR.S552487
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Bilikere Dwarakanath
Jinying Li,1,* Yifei Zhang,2,* Xuemei Wang,3 Zhongyu Ding,3 Na Zhu,1 Yuan Chen,3 Yongli Li,1 Chuangxin Lu4
1Department of Health Management, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China; 2Department of Cadre Healthcare, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China; 3Department of Traditional Chinese Medicine, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China; 4Department of Medical Oncology, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yongli Li, Department of Health Management, Henan Provincial People’s Hospital, No. 7 Weiwu Road, Zhengzhou, Henan, 450001, People’s Republic of China, Tel +86-0371-65580321, Email nthdxtq2454@126.com Chuangxin Lu, Department of Medical Oncology, Henan Provincial People’s Hospital, No. 7 Weiwu Road, Zhengzhou, Henan, 450001, People’s Republic of China, Tel +86-0371-65580321, Email xa7057@yeah.net
Background: Non-small cell lung cancer (NSCLC) is a prevalent malignancy where adjuvant therapy is crucial. Astragalus polysaccharide injection (APS-I) has shown potential as an adjunct due to its immunomodulatory properties, but its impact on survival outcomes requires further validation.
Objective: This study employed propensity score matching (PSM) to evaluate the efficacy of APS-I combined with conventional therapy versus conventional therapy alone in the adjuvant treatment of NSCLC.
Methods: In this retrospective cohort study, NSCLC patients receiving adjuvant therapy between January 2018 and December 2024 were enrolled. After 1:1 PSM, 54 matched pairs were allocated to the APS-I + conventional therapy group or the conventional therapy alone group. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), immune function, quality of life (QoL), and adverse events.
Results: The APS-I group demonstrated significantly superior short-term efficacy, with higher ORR (77.8% vs 33.3%, P< 0.001) and DCR (96.3% vs 70.4%, P< 0.001). Survival outcomes were significantly improved: median PFS was 12.8 months versus 8.2 months (Hazard Ratio [HR]= 0.143, 95% CI: 0.082– 0.250, P< 0.001), and median OS was 23.3 months versus 17.0 months (HR= 0.249, 95% CI: 0.154– 0.401, P< 0.001). The APS-I group also showed a significantly higher Karnofsky Performance Status (KPS) improvement rate (60.5% vs 27.9%, P=0.003) and a lower incidence of adverse events (11.1% vs 33.3%, P=0.014).
Conclusion: APS-I combined with conventional therapy shows promise in improving survival and quality of life, but multicenter RCTs are warranted to validate efficacy before clinical adoption.
Keywords: astragalus polysaccharide injection, non-small cell lung cancer (NSCLC), adjuvant therapy, propensity score matching (PSM), retrospective study, survival prognosis
1Department of Health Management, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China; 2Department of Cadre Healthcare, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China; 3Department of Traditional Chinese Medicine, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China; 4Department of Medical Oncology, Henan Provincial People’s Hospital, Zhengzhou, 450001, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yongli Li, Department of Health Management, Henan Provincial People’s Hospital, No. 7 Weiwu Road, Zhengzhou, Henan, 450001, People’s Republic of China, Tel +86-0371-65580321, Email nthdxtq2454@126.com Chuangxin Lu, Department of Medical Oncology, Henan Provincial People’s Hospital, No. 7 Weiwu Road, Zhengzhou, Henan, 450001, People’s Republic of China, Tel +86-0371-65580321, Email xa7057@yeah.net
Background: Non-small cell lung cancer (NSCLC) is a prevalent malignancy where adjuvant therapy is crucial. Astragalus polysaccharide injection (APS-I) has shown potential as an adjunct due to its immunomodulatory properties, but its impact on survival outcomes requires further validation.
Objective: This study employed propensity score matching (PSM) to evaluate the efficacy of APS-I combined with conventional therapy versus conventional therapy alone in the adjuvant treatment of NSCLC.
Methods: In this retrospective cohort study, NSCLC patients receiving adjuvant therapy between January 2018 and December 2024 were enrolled. After 1:1 PSM, 54 matched pairs were allocated to the APS-I + conventional therapy group or the conventional therapy alone group. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), immune function, quality of life (QoL), and adverse events.
Results: The APS-I group demonstrated significantly superior short-term efficacy, with higher ORR (77.8% vs 33.3%, P< 0.001) and DCR (96.3% vs 70.4%, P< 0.001). Survival outcomes were significantly improved: median PFS was 12.8 months versus 8.2 months (Hazard Ratio [HR]= 0.143, 95% CI: 0.082– 0.250, P< 0.001), and median OS was 23.3 months versus 17.0 months (HR= 0.249, 95% CI: 0.154– 0.401, P< 0.001). The APS-I group also showed a significantly higher Karnofsky Performance Status (KPS) improvement rate (60.5% vs 27.9%, P=0.003) and a lower incidence of adverse events (11.1% vs 33.3%, P=0.014).
Conclusion: APS-I combined with conventional therapy shows promise in improving survival and quality of life, but multicenter RCTs are warranted to validate efficacy before clinical adoption.
Keywords: astragalus polysaccharide injection, non-small cell lung cancer (NSCLC), adjuvant therapy, propensity score matching (PSM), retrospective study, survival prognosis